Edesa Biotech, Inc. (EDSA)
| Market Cap | 14.46M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.37M |
| Shares Out | 3.16M |
| EPS (ttm) | -2.93 |
| PE Ratio | n/a |
| Forward PE | 0.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,826 |
| Open | 4.33 |
| Previous Close | 4.49 |
| Day's Range | 4.33 - 4.79 |
| 52-Week Range | 2.46 - 19.67 |
| Beta | 0.85 |
| Analysts | Strong Buy |
| Price Target | 39.00 (+753.39%) |
| Earnings Date | Feb 9, 2024 |
About EDSA
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic cont... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for EDSA stock is "Strong Buy." The 12-month stock price forecast is $39.0, which is an increase of 753.39% from the latest price.
News
Edesa Biotech Reports Fiscal Year 2023 Results
TORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory di...
Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study
1.0% Formulation Reached Primary Endpoint with Statistical Significance Full Analysis Identified Additional Efficacy Signals TORONTO, ON / ACCESSWIRE / November 20, 2023 / Edesa Biotech, Inc. (NASDAQ:...
Edesa Biotech to Present at Dermatology Drug Development Summit
TORONTO, ON / ACCESSWIRE / October 26, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr...
Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug
TORONTO, ON / ACCESSWIRE / October 25, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that He...
Edesa Biotech Secures $10 Million Credit Facility with Company Founder
Revolving Line of Credit to Support Completion of Government-Funded ARDS Study TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa", or the "Company"), a clinical-s...
Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government
TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitmen...
Edesa Biotech Announces One-for-Seven Reverse Share Split
TORONTO, ON / ACCESSWIRE / October 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa" or the "Company"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseas...
Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate
Company's host-directed therapeutic, EB05 (paridiprubart), demonstrated a statistically significant mortality reduction among critically ill patients with severe respiratory disease TORONTO, ON / ACCE...
Edesa Biotech Reports Fiscal Third Quarter 2023 Results
TORONTO, ON / ACCESSWIRE / August 9, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial ...
Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference
TORONTO, ON / ACCESSWIRE / July 26, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the c...
Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens
Positive Findings Support Potential Expanded Uses for Paridiprubart TORONTO, ON / ACCESSWIRE / June 28, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on ...
Edesa Biotech Appoints Biotech Deal Veteran to CFO Role
TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the c...
Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name
TORONTO, ON / ACCESSWIRE / June 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today the assign...
Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results
TORONTO, ON / ACCESSWIRE / May 11, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial re...
Edesa Biotech to Participate in Swiss Biotech Day
TORONTO, ON / ACCESSWIRE / April 20, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the ...
The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate
International name assignment is a key step in Edesa's development and commercialization plans TORONTO, ON / ACCESSWIRE / April 4, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmac...
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference
TORONTO, ON / ACCESSWIRE / March 23, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the ...
Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting
TORONTO, ON / ACCESSWIRE / March 16, 2023 / Edesa Biotech, Inc. announced today that the company has been selected to present clinical trial data from a Phase 2B multi-dose study of its EB01 drug cand...
Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study
28-day survival will be evaluated in ARDS patients hospitalized with Covid-19 Updated protocol approved by study's ethics committee Company exploring pathways for treating general ARDS patients TORONT...
Edesa Biotech Reports Fiscal 1st Quarter 2023 Results
TORONTO, ON / ACCESSWIRE / February 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financi...
Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study
Company's biologic drug candidate targets a key pathway involved in the progression and maintenance of depigmentation. TORONTO, ON / ACCESSWIRE / February 1, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), ...
Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug
Study successfully identified lowest effective dose 1.0% formulation reached primary endpoint with statistical significance Company preparing for End of Phase 2 meeting with FDA following full analysi...
FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate
Fast Track improves the speed and frequency of communication with FDA, potentially leading to earlier drug approval and access by patients. TORONTO, ON / ACCESSWIRE / December 20, 2022 / Edesa Biotech...
Edesa Biotech Reports Fiscal Year 2022 Results
TORONTO, ON / ACCESSWIRE / December 16, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financi...
Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference
TORONTO, ON / ACCESSWIRE / December 2, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr...